C-reactive protein as a prognostic marker in lymphocytic myocarditis

Japanese Heart Journal

Volumn 41, Issue 1, 2000, Pages 41-47

  Kaneko, Katsumi ^a   Kanda, Tsugiyasu ^a,b   Hasegawa, Akira ^a   Suzuki, Tadashi ^a   Kobayashi, Isao ^a   Nagai, Ryozo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Cardiomyopathy; Heart failure; Survival

Indexed keywords

ANTIARRHYTHMIC AGENT; C REACTIVE PROTEIN; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MORBIDITY; MORTALITY; MYOCARDITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SURVIVAL TIME;

EID: 0034080878     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.41.41     Document Type: Article

References (15)

1. Pisani B, Taylor DO, Mason JW. Inflammatory myocardial diseases and cardiomyopathies. Am J Med 1997; 102: 459-69.
2. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 1995; 333: 269-75.
3. Smith SC, Landerson JH, Mason JW, et al. Detection of myocarditis by cardiac troponin-I. (Abstract) Circulation 1994; 90: 1-547.
4. Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Leingham JGG, Warrell DA, editors. Oxford Textbook of Medicine, third edition. Oxford: Oxford University Press, 1995; 1527-33.
5. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for C-reactive protein. Clin Chem Acta 1981; 117: 13-23.
6. Taylor DO, Mason JW. Myocarditis. In: Cardiology. Philadelphia: Lippincott-Raven, 1996; Vol. 2, 47: 1-26.
7. Pietila K, Harmonien A, Teppo AM. Acute phase reaction, infarct size and in-hospital morbidity in myocardial infarction patients treated with streptokinase or recombinant tissue type plasminogen activator. Ann Med 1991; 23: 529-35.
8. Anzai T, Yoshikawa T, Shiraki H, et al. Protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997; 96: 778-84.
9. Kaneko K, Kanda T, Nakazato Y, et al. Expression of interleukin-6 in myocardium and coronary arteries in patients with myocardial infarction. Res Comm Mol Pathol Pharmacol 1997; 97: 3-12.
10. Matsumori A, Yamada T, Suzuki H, et al. Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994; 72: 561-6.
11. O'Connell JB. The role of myocarditis in end-stage dilated cardioamyopathy. Texas Heart Institute 1987; 14: 268-75.
12. Kanda T, Araki M, Nakano M, et al. Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exp Ther 1995; 273: 955-8.
13. Mendes LA, Dec GW, Picard MH. Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. Am Heart J 1994; 128: 301-7.
14. Miric M, Miskovic A, Brkic-S, et al. Long-term follow-up of patients with myocarditis and idiopathic dilated cardiomyopathy after immunomodulatory therapy. FEMS Immunol Med Microbiol 1994; 10: 65-74.
15. McNamara DM, Rosenblum WD, Janosko KM, et al. Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997; 95: 2476-78.